VAM-IHCA

Title

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) -  A Randomized, Double-Blind, Placebo-Controlled Trial

Aim

To improve patient survival and neurological outcome of cardiac arrest.

Methods

The VAM-IHCA trial is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled at multiple hospitals in Denmark. Included patients will be randomized in a 1:1 ratio to either vasopressin (up to 80 IU) and methylprednisolone (40 mg) or placebo.

Population

In-hospital cardiac arrest occur in approximately 2000 - 2500 patients per year in Denmark. Of these patients, approximately 60% achieve return of spontaneous circulation, but only 30% survive 30 days after the cardiac arrest.

Perspective

The VAM-IHCA trial is a national Danish study that has the potential to change international guidelines for treatment of cardiac arrest.

Collaborators

Aalborg University Hospital, Regional Hospital Randers, Regional Hospital Viborg, Regional Hospital Horsens, Odense University Hospital, Herlev Hospital , Gentofte Hospital, Rigshospitalet, Aarhus University Hospital.

Contact